Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.

NSCLC: Sensitizing EGFR mutation positive...erlotinib + bevacizumab (nonsqumous)…The panel also added erlotinib/bevacizumab as a first-line therapy option for patients with EGFR positive metastatic NSCLC

Progression-free survival (PFS) was 17.9 months (95% confidence interval [CI], 15.2-19.9) for bevacizumab plus erlotinib and 11.2 months (95% CI, 9.7-13.8) for erlotinib only (hazard ratio [HR] = 0.55; 95% CI, 0.41-0.73; p < 0.001). A brain metastases subgroup treated with bevacizumab plus erlotinib also showed improved PFS (HR = 0.48; 95% CI, 0.27-0.84; p = 0.008)...Bevacizumab plus erlotinib significantly improved PFS in patients with untreated metastatic EGFR-mutated NSCLC, including those with brain metastases at baseline.

BE as a combination of EGFR-TKIs and VEGF inhibitors achieved durable response, especially absence of CNS mets. BE is a promising regimen for EGFR-mutated NSCLC.

Chemotherapy-naïve pts with advanced non-squamous NSCLC harbouring EGFR-mutation were randomly assigned to receive either combination with erlotinib (150 mg daily) plus bevacizumab...Pts were followed up for a median of 12.4 months. The interim analysis showed that the study met its primary endpoint. At data cutoff (Sept 21, 2017), median PFS was 16.9 months (95% CI 14.2-21.0) in BE and 13.3 months (11.1-15.3) in E (p = 0.0157) (HR 0.605, 95% CI 0.417-0.877).

Patients aged at least 18 years with metastatic or locally advanced non-squamous NSCLC harboring an activating EGFR mutation were eligible....At a median follow-up of 36.3 months (95% CI: 30.7–40.9), 140 PFS events (87.5%) were reported, 72 (90.0%) with erlotinib and 68 (85.0%) with erlotinib plus bevacizumab. Median IA-PFS was 9.6 months (95% CI: 8.2–10.6) with erlotinib and 15.4 months (95% CI: 12.2–18.6) with erlotinib plus bevacizumab (Fig. 2A). At multivariable analysis, a statistically significant advantage for erlotinib plus bevacizumab in IA-PFS was confirmed (HR = 0.66 [95% CI: 0.47–0.92], p = 0.015; Supplementary Table 1).

The results of this interim analysis showed that bevacizumab plus erlotinib combination therapy improves progression-free survival compared with erlotinib alone in patients with EGFR-positive NSCLC.

JO25567 was open-label randomized trial. Patients with stage 3b/4 or recurrent non-squamous EGFR mutation–positive NSCLC and no previous chemotherapy were randomly allocated to receive EB...Forty OS events (53.3%) had occurred in EB and 49 events (63.6%) in E. Five-year survival rate was 41% in EB and 35% in E.

The JO25567 study was a randomized phase II study to investigate the efficacy of the combination therapy consisted with erlotinib and bevacizumab for non-squamous non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) activating mutation.